Kamada (KMDA) Cash from Financing Activities (2012 - 2026)
Kamada's (KMDA) quarterly Cash from Financing Activities came in at -$19.0 million in Q2 2026, down 17.85% on a YoY basis from -$23.1 million in Q2 2025, and down 2119.16% quarter-over-quarter from -$856000.0 in Q1 2026.
Analysis
Kamada (KMDA) Cash from Financing Activities (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Cash from Financing Activities for 15 consecutive years, with -$19.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash from Financing Activities fell 17.85% year-over-year to -$19.0 million; the trailing twelve-month figure through Jun 2026 stood at -$21.8 million (up 0.55% YoY), and the FY2025 full-year result was -$18.3 million, down 31.87% from the prior year.
- Cash from Financing Activities eased to -$19.0 million in Q2 2026 per KMDA's latest filing, from -$856000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $31.3 million in Q3 2023 and bottomed at -$19.0 million in Q2 2026.
- Historically, Cash from Financing Activities has averaged -$2.2 million across 5 years, with a median of -$2.3 million in 2022.
- The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities tumbled 608.78% in 2022, then surged 1484.12% in 2023.
- Over 5 years, Cash from Financing Activities stood at -$2.9 million in 2022, then jumped by 44.93% to -$1.6 million in 2023, then jumped by 55.22% to -$708000.0 in 2024, then tumbled by 66.53% to -$1.2 million in 2025, then plunged by 1511.2% to -$19.0 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$19.0 million, -$856000.0, and -$1.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | -1.48 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 2.34 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -426.70 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -1.22 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 14.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 1.30 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -181.51 Mn |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn | -19.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -19.00 Mn |
| Mar 31, 2026 | -856,000.00 |
| Dec 31, 2025 | -1.18 Mn |
| Sep 30, 2025 | -754,000.00 |
| Jun 30, 2025 | -16.12 Mn |
| Mar 31, 2025 | -293,000.00 |
| Dec 31, 2024 | -708,000.00 |
| Sep 30, 2024 | -4.79 Mn |
| Jun 30, 2024 | -2.68 Mn |
| Mar 31, 2024 | -5.74 Mn |
| Dec 31, 2023 | -1.58 Mn |
| Sep 30, 2023 | 31.30 Mn |
| Jun 30, 2023 | -5.86 Mn |
| Mar 31, 2023 | -2.88 Mn |
| Dec 31, 2022 | -2.87 Mn |
| Sep 30, 2022 | -2.26 Mn |
| Jun 30, 2022 | -2.40 Mn |
| Mar 31, 2022 | -1.81 Mn |
| Dec 31, 2021 | 19.70 Mn |
| Sep 30, 2021 | -319,000.00 |